{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:24:21Z","timestamp":1790504661589,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T00:00:00Z","timestamp":1503014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T00:00:00Z","timestamp":1503014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA169365"],"award-info":[{"award-number":["1R01CA169365"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01EB021336"],"award-info":[{"award-number":["1R01EB021336"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA014520"],"award-info":[{"award-number":["P30CA014520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32GM08349"],"award-info":[{"award-number":["5T32GM08349"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM008505"],"award-info":[{"award-number":["T32GM008505"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DGE-1256259"],"award-info":[{"award-number":["DGE-1256259"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["125246-RSG-13-099-01-CCE"],"award-info":[{"award-number":["125246-RSG-13-099-01-CCE"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00259-017-3793-2","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T19:32:59Z","timestamp":1503084779000},"page":"123-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody"],"prefix":"10.1007","volume":"45","author":[{"given":"Emily B.","family":"Ehlerding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saige","family":"Lacognata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina A.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin J.","family":"Jeffery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles P.","family":"Theuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,18]]},"reference":[{"issue":"6","key":"3793_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nm0603-653","volume":"9","author":"P Carmeliet","year":"2003","unstructured":"Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653\u201360.","journal-title":"Nat Med"},{"issue":"Suppl","key":"3793_CR2","doi-asserted-by":"publisher","first-page":"S224","DOI":"10.1016\/j.semcancer.2015.01.001","volume":"35","author":"Z Wang","year":"2015","unstructured":"Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 2015;35 Suppl:S224\u2013S43. doi:\n                    10.1016\/j.semcancer.2015.01.001\n                    \n                  .","journal-title":"Semin Cancer Biol"},{"issue":"23","key":"3793_CR3","doi-asserted-by":"publisher","first-page":"7871","DOI":"10.1158\/1078-0432.ccr-08-0593","volume":"14","author":"HJ Burstein","year":"2008","unstructured":"Burstein HJ, Chen Y-H, Parker LM, Savoie J, Younger J, Kuter I, et al. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008;14(23):7871\u20137. doi:\n                    10.1158\/1078-0432.ccr-08-0593\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3793_CR4","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1245\/s10434-014-4335-9","volume":"22","author":"JH Choe","year":"2015","unstructured":"Choe JH, Overman MJ, Fournier KF, Royal RE, Ohinata A, Rafeeq S, et al. Improved survival with anti-VEGF therapy in the treatment of unresectable appendiceal epithelial neoplasms. Ann Surg Oncol. 2015;22(8):2578\u201384. doi:\n                    10.1245\/s10434-014-4335-9\n                    \n                  .","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"3793_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11060-015-1808-z","volume":"124","author":"BS Kim","year":"2015","unstructured":"Kim BS, Kim SK, Choi SH, Lee S-H, Seol HJ, Nam D-H, et al. Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas. J Neurooncol. 2015;124(1):101\u201310. doi:\n                    10.1007\/s11060-015-1808-z\n                    \n                  .","journal-title":"J Neurooncol"},{"issue":"10","key":"3793_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077117","volume":"8","author":"CH Lieu","year":"2013","unstructured":"Lieu CH, Tran H, Jiang Z-Q, Mao M, Overman MJ, Lin E, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013;8(10):e77117. doi:\n                    10.1371\/journal.pone.0077117\n                    \n                  .","journal-title":"PLoS One"},{"issue":"17","key":"3793_CR7","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.1158\/1078-0432.ccr-11-1185","volume":"17","author":"C Carbone","year":"2011","unstructured":"Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, et al. Anti-VEGF treatment\u2013resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res. 2011;17(17):5822\u201332. doi:\n                    10.1158\/1078-0432.ccr-11-1185\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3793_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00428-013-1463-8","volume":"463","author":"Y Miyata","year":"2013","unstructured":"Miyata Y, Sagara Y, Watanabe S-i, Asai A, Matsuo T, Ohba K, et al. CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34. Virchows Arch. 2013;463(5):673\u20139. doi:\n                    10.1007\/s00428-013-1463-8\n                    \n                  .","journal-title":"Virchows Arch"},{"issue":"4","key":"3793_CR9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/IGC.0b013e31823c36b8","volume":"22","author":"P Liu","year":"2012","unstructured":"Liu P, Sun YL, Du J, Hou XS, Meng H. CD105\/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer. Int J Gynecol Cancer. 2012;22(4):586\u201392. doi:\n                    10.1097\/IGC.0b013e31823c36b8\n                    \n                  .","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"3793_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s12253-015-9937-4","volume":"21","author":"L Zhou","year":"2015","unstructured":"Zhou L, Yu L, Ding G, Chen W, Zheng S, Cao L. Overexpressions of DLL4 and CD105 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma. Pathol Oncol Res. 2015;21(4):1141\u20137. doi:\n                    10.1007\/s12253-015-9937-4\n                    \n                  .","journal-title":"Pathol Oncol Res"},{"issue":"7","key":"3793_CR11","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1158\/1078-0432.ccr-07-4478","volume":"14","author":"NA Dallas","year":"2008","unstructured":"Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14(7):1931\u20137. doi:\n                    10.1158\/1078-0432.ccr-07-4478\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3793_CR12","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00259-011-1765-5","volume":"38","author":"H Hong","year":"2011","unstructured":"Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging. 2011;38(7):1335\u201343. doi:\n                    10.1007\/s00259-011-1765-5\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"3793_CR13","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1158\/1078-0432.ccr-12-0098","volume":"18","author":"LS Rosen","year":"2012","unstructured":"Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, et al. A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin Cancer Res. 2012;18(17):4820\u20139. doi:\n                    10.1158\/1078-0432.ccr-12-0098\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3793_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clgc.2016.05.010","volume":"15","author":"AB Apolo","year":"2017","unstructured":"Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee M-J, et al. A phase II clinical trial of TRC105 (anti-Endoglin antibody) in adults with advanced\/metastatic urothelial carcinoma. Clin Genitourin Cancer. 2017;15(1):77\u201385. doi:\n                    10.1016\/j.clgc.2016.05.010\n                    \n                  .","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"3793_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/2050640615583587","volume":"3","author":"AG Duffy","year":"2015","unstructured":"Duffy AG, Ulahannan SV, Cao L, Rahma OE, Makarova-Rusher OV, Kleiner DE, et al. A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. United European Gastroenterol J. 2015;3(5):453\u201361. doi:\n                    10.1177\/2050640615583587\n                    \n                  .","journal-title":"United European Gastroenterol J"},{"issue":"23","key":"3793_CR16","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1158\/1078-0432.ccr-14-1143","volume":"20","author":"MS Gordon","year":"2014","unstructured":"Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, et al. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014;20(23):5918\u201326. doi:\n                    10.1158\/1078-0432.ccr-14-1143\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3793_CR17","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/bju.12986","volume":"116","author":"FH Karzai","year":"2015","unstructured":"Karzai FH, Apolo AB, Cao L, Madan RA, Adelberg DE, Parnes H, et al. A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. BJU Int. 2015;116(4):546\u201355. doi:\n                    10.1111\/bju.12986\n                    \n                  .","journal-title":"BJU Int"},{"key":"3793_CR18","doi-asserted-by":"publisher","unstructured":"Gudkov VS, Shilyagina YN, Vodeneev AV, Zvyagin VA. Targeted radionuclide therapy of human tumors. Int J Mol Sci. 2016;17(1). doi:\n                    10.3390\/ijms17010033\n                    \n                  .","DOI":"10.3390\/ijms17010033"},{"issue":"2","key":"3793_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2967\/jnumed.113.135178","volume":"55","author":"F Fahey","year":"2014","unstructured":"Fahey F, Zukotynski K, Capala J, Knight N; Organizing Committee, Contributors, and Participants of NCI\/SNMMI Joint Workshop on Targeted Radionuclide Therapy. Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging. J Nucl Med. 2014;55(2):337\u201348. doi:\n                    10.2967\/jnumed.113.135178\n                    \n                  .","journal-title":"J Nucl Med"},{"issue":"S4","key":"3793_CR20","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/cncr.24792","volume":"116","author":"P-Y Salaun","year":"2010","unstructured":"Salaun P-Y, Bodet-Milin C, Frampas E, Oudoux A, Sa\u00ef-Maurel C, Faivre-Chauvet A, et al. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer. 2010;116(S4):1053\u20138. doi:\n                    10.1002\/cncr.24792\n                    \n                  .","journal-title":"Cancer"},{"issue":"12","key":"3793_CR21","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00259-002-0997-9","volume":"29","author":"X-F Li","year":"2002","unstructured":"Li X-F, Kinuya S, Yokoyama K, Koshida K, Mori H, Shiba K, et al. Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells. Eur J Nucl Med Mol Imaging. 2002;29(12):1669\u201374. doi:\n                    10.1007\/s00259-002-0997-9\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"3793_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.ijrobp.2014.10.047","volume":"91","author":"H-J Lee","year":"2015","unstructured":"Lee H-J, Yoon C, Park DJ, Kim Y-J, Schmidt B, Lee Y-J, et al. Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1\u03b1 maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature. Int J Radiat Oncol Biol Phys. 2015;91(3):621\u201330. doi:\n                    10.1016\/j.ijrobp.2014.10.047\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7-8","key":"3793_CR23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.apradiso.2009.02.006","volume":"67","author":"S-Y Lee","year":"2009","unstructured":"Lee S-Y, Hong Y-D, Pyun M-S, Felipe PM, Choi S-J. Radiolabeling of monoclonal anti-vascular endothelial growth factor receptor 1 (VEGFR 1) with 177Lu for potential use in radioimmunotherapy. Appl Radiat Isot. 2009;67(7-8):1185\u20139. doi:\n                    10.1016\/j.apradiso.2009.02.006\n                    \n                  .","journal-title":"Appl Radiat Isot"},{"issue":"7","key":"3793_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1089\/cbr.2012.1224","volume":"27","author":"SA Ashrafi","year":"2012","unstructured":"Ashrafi SA, Hosseinimehr SJ, Varmira K, Abedi SM. Radioimmunotherapy with 131I-bevacizumab as a specific molecule for cells with overexpression of the vascular endothelial growth factor. Cancer Biother Radiopharm. 2012;27(7):420\u20135. doi:\n                    10.1089\/cbr.2012.1224\n                    \n                  .","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"3793_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2967\/jnumed.116.177857","volume":"58","author":"CG England","year":"2017","unstructured":"England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, et al. Preclinical pharmacokinetics and biodistribution studies of 89Zr-labeled pembrolizumab. J Nucl Med. 2017;58(1):162\u20138.","journal-title":"J Nucl Med"},{"issue":"1","key":"3793_CR26","first-page":"1","volume":"2","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Hong H, Engle JW, Yang Y, Barnhart TE, Cai W. Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am J Nucl Med Mol Imaging. 2012;2(1):1\u201313.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"1","key":"3793_CR27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s00259-011-1930-x","volume":"39","author":"H Hong","year":"2012","unstructured":"Hong H, Severin GW, Yang Y, Engle JW, Zhang Y, Barnhart TE, et al. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging. 2012;39(1):138\u201348. doi:\n                    10.1007\/s00259-011-1930-x\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"3793_CR28","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023\u20137.","journal-title":"J Nucl Med"},{"key":"3793_CR29","doi-asserted-by":"publisher","unstructured":"Sabet A, Biersack H-J, Ezziddin S. Advances in peptide receptor radionuclide therapy. Semin Nucl Med. 2016;46(1):40\u20136. doi:\n                    10.1053\/j.semnuclmed.2015.09.005\n                    \n                  .","DOI":"10.1053\/j.semnuclmed.2015.09.005"},{"key":"3793_CR30","doi-asserted-by":"publisher","unstructured":"Ehlerding EB, England CG, McNeel DG, Cai W. Molecular imaging of immunotherapy targets in cancer. J Nucl Med. 2016;57(10):1487\u201392. doi:\n                    10.2967\/jnumed.116.177493\n                    \n                  .","DOI":"10.2967\/jnumed.116.177493"},{"issue":"6","key":"3793_CR31","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2967\/jnumed.112.111534","volume":"54","author":"F Al-Ejeh","year":"2013","unstructured":"Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, et al. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. J Nucl Med. 2013;54(6):913\u201321. doi:\n                    10.2967\/jnumed.112.111534\n                    \n                  .","journal-title":"J Nucl Med"},{"issue":"6","key":"3793_CR32","doi-asserted-by":"publisher","first-page":"899","DOI":"10.18632\/oncotarget.1037","volume":"4","author":"JY Wagner","year":"2013","unstructured":"Wagner JY, Schwarz K, Schreiber S, Schmidt B, Wester HJ, Schwaiger M, et al. Myeloablative anti-CD20 radioimmunotherapy +\/\u2212 high-dose chemotherapy followed by autologous stem cell support for relapsed\/refractory B-cell lymphoma results in excellent long-term survival. Oncotarget. 2013;4(6):899\u2013910. doi:\n                    10.18632\/oncotarget.1037\n                    \n                  .","journal-title":"Oncotarget"},{"issue":"3","key":"3793_CR33","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","volume":"31","author":"OW Press","year":"2013","unstructured":"Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013;31(3):314\u201320. doi:\n                    10.1200\/JCO.2012.42.4101\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"1","key":"3793_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2967\/jnumed.116.173922","volume":"58","author":"J Blakkisrud","year":"2017","unstructured":"Blakkisrud J, L\u00f8ndalen A, Martinsen ACT, Dahle J, Holtedahl JE, Bach-Gansmo T, et al. Tumor-absorbed dose for non-Hodgkin lymphoma patients treated with the anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan. J Nucl Med. 2017;58(1):48\u201354. doi:\n                    10.2967\/jnumed.116.173922\n                    \n                  .","journal-title":"J Nucl Med"},{"issue":"3","key":"3793_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120561","volume":"10","author":"SHL Frost","year":"2015","unstructured":"Frost SHL, Frayo SL, Miller BW, Orozco JJ, Booth GC, Hylarides MD, et al. Comparative efficacy of (177)Lu and (90)Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models. PLoS One. 2015;10(3):e0120561. doi:\n                    10.1371\/journal.pone.0120561\n                    \n                  .","journal-title":"PLoS One"},{"issue":"12","key":"3793_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028005","volume":"6","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Hong H, Engle JW, Bean J, Yang Y, Leigh BR, et al. Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS One. 2011;6(12):e28005. doi:\n                    10.1371\/journal.pone.0028005\n                    \n                  .","journal-title":"PLoS One"},{"issue":"5","key":"3793_CR37","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00259-012-2334-2","volume":"40","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Hong H, Orbay H, Valdovinos HF, Nayak TR, Theuer CP, et al. PET imaging of CD105\/endoglin expression with a 61\/64Cu-labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging. 2013;40(5):759\u201367. doi:\n                    10.1007\/s00259-012-2334-2\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-017-3793-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3793-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3793-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:01:21Z","timestamp":1589626881000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-017-3793-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,18]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3793"],"URL":"https:\/\/doi.org\/10.1007\/s00259-017-3793-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,18]]},"assertion":[{"value":"6 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This work was supported, in part, by the University of Wisconsin \u2013 Madison, the National Institutes of Health (NIBIB\/NCI 1R01CA169365, 1R01EB021336, P30CA014520, 5T32GM08349, T32GM008505), the National Science Foundation (DGE-1256259) and the American Cancer Society (125246-RSG-13-099-01-CCE).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}},{"value":"C.P. Theuer is the CEO of TRACON Pharmaceuticals. No potential conflicts of interest were disclosed by the other authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}